Catalent to acquire Vaccine Manufacturing and Innovation Centre UK Limited's Business
Press releases | April 6, 2022
Fried Frank advised Catalent, Inc. (“Catalent”) on its acquisition of the business and assets of Vaccine Manufacturing and Innovation Centre UK Limited (“VMIC”), including a biologics development and manufacturing facility (“Facility”) currently under construction at the renowned Harwell Science and Innovation Campus, located close to Oxford, UK.
VMIC was established by the University of Oxford, Imperial College London and the London School of Hygiene and Tropical Medicine. Construction of the facility, which has been designed as a cutting-edge centre of vaccine excellence, has to date been funded with grant funding provided by the UK government. The facility was originally intended to serve as the national response capability for the UK government in order to produce vaccines against future pandemics/ emerging infectious diseases, and deliberate/accidental release of biological agents.
Catalent, which is listed on the New York Stock Exchange and a member of the S&P 500 with a market cap of approximately US$20 billion, is the global leader in enabling pharma, biotech and consumer health partners to optimize product development, launch and full life-cycle supply for patients around the word. Catalent plans to invest up to US$160 million to complete the Facility and equip it with state-of-the-art capabilities for the development and manufacture of biologic therapies and vaccines, including mRNA, proteins and other advanced modalities. It is expected that the Facility will employ more than 400 people and support public and private organizations seeking to develop and manufacture therapeutics. This acquisition builds on Catalent's longstanding presence in the UK, where its workforce already exceeds 1,300 people across four existing facilities.
The Fried Frank team was led by corporate partner Steven Epstein, and the London team was led by corporate partner Ian Lopez and included antitrust and competition partner Tobias Caspary; corporate real estate partner Patrick Williams; tax partner Nick Thornton; antitrust and competition special counsel Neda Moussavi; corporate associates James Frecknall, Cormac McGrady and Adrian Packer; antitrust and competition associate Romain Girard; corporate real estate associate Joseph Patchitt; and tax associate Richard Pilgrim.
This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.